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Bristol-Myers Squulmonary hypertension (PH) is deﬁned by a mean pulmonary artery pressure 25 mm Hg at rest, measured
during right heart catheterization. There is still insufﬁcient evidence to add an exercise criterion to this deﬁnition.
The term pulmonary arterial hypertension (PAH) describes a subpopulation of patients with PH characterized
hemodynamically by the presence of pre-capillary PH including an end-expiratory pulmonary artery wedge pressure
(PAWP) 15 mm Hg and a pulmonary vascular resistance >3 Wood units. Right heart catheterization remains
essential for a diagnosis of PH or PAH. This procedure requires further standardization, including uniformity of the
pressure transducer zero level at the midthoracic line, which is at the level of the left atrium. One of the most
common problems in the diagnostic workup of patients with PH is the distinction between PAH and PH due to left
heart failure with preserved ejection fraction (HFpEF). A normal PAWP does not rule out the presence of HFpEF.
Volume or exercise challenge during right heart catheterization may be useful to unmask the presence of left heart
disease, but both tools require further evaluation before their use in general practice can be recommended. Early
diagnosis of PAH remains difﬁcult, and screening programs in asymptomatic patients are feasible only in high-risk
populations, particularly in patients with systemic sclerosis, for whom recent data suggest that a combination of
clinical assessment and pulmonary function testing including diffusion capacity for carbon monoxide, biomarkers,
and echocardiography has a higher predictive value than echocardiography alone. (J Am Coll Cardiol 2013;62:
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Abbreviations
and Acronyms
CO = cardiac output
CTD = connective tissue
disease
DLCO = diffusion capacity for
carbon monoxide
HFpEF = heart failure with
preserved ejection fraction
HPAH = heritable pulmonary
arterial hypertension
IPAH = idiopathic pulmonary
arterial hypertension
LVEDP = left ventricular end-
diastolic pressure
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
PAH = pulmonary arterial
hypertension
PAPm = mean pulmonary
artery pressure




PVR = pulmonary vascular
resistance
RHC = right heart
catheterization
SSc = scleroderma
WU = Wood units
JACC Vol. 62, No. 25, Suppl D, 2013 Hoeper et al.
December 24, 2013:D42–50 Definition and Diagnosis of PH
D43Nice, France, the working group on diagnosis and assess-
ment did not attempt to fully revise previous recommen-
dations but proposed changes only where strong new
evidence has been generated to support new proposals.
Deﬁnitions, Limitations, Uncertainties,
and Controversies
Some aspects of the deﬁnitions and recommendations
derived from the 4th WSPH have remained controversial.
Debates are still ongoing, especially regarding the following
questions. 1) Should PH be deﬁned by a resting mean
pulmonary artery pressure (PAPm) 25 mm Hg as is
currently the case or by a resting PAPm >20 mm Hg and
should the term “borderline PH” be introduced for patients
with a PAPm between 21 and 24 mm Hg? 2) Should
exercise-induced PH be reintroduced as part of the PH
deﬁnition? 3) Should pulmonary vascular resistance (PVR)
be included in the PH/PAH deﬁnition? 4) Is pulmonary
artery wedge pressure (PAWP) of 15 mm Hg appropriate to
distinguish between pre-capillary and post-capillary PH and
how should PAWP be measured? 5) Should ﬂuid or exercise
challenge be used to distinguish patients with PAH from
patients with PH due to left ventricular (LV) dysfunction?
Should PH be deﬁned by a resting PAPm ‡25 mm Hg as
is currently the case or by a resting PAPm >20 mm Hg
and should the term “borderline PH” be introduced for
patients with a PAPm between 21 and 24 mm Hg? A
resting PAPm >25 mm Hg has been the cutoff value for
a diagnosis of manifest PH since the 1st WSPH. However,
the upper level of normal for resting PAPm is 20 mmHg (5),
and it is unclear how to classify and manage patients with
PAPm levels between 21 and 24 mm Hg. Most of the
relevant epidemiological and therapeutic studies in the ﬁeld
of PAH have used the 25 mm Hg threshold, and little is
known about patients with PAPm levels between 21 and
24 mm Hg.
Several studies have suggested that even mildly elevated
PA pressures may be of prognostic signiﬁcance, particularly
in patients with lung disease or connective tissue disease
(CTD) (6,7). Introduction of the term “borderline PH” for
patients with a PAPm ranging from 21 to 24 mm Hg was
discussed in Dana Point and in Nice (8). This term could be
used to avoid labeling patients with PAPm values between
21 and 24 mm Hg as manifest PH/PAH but at the same
time would ensure that such values are not labeled “healthy.”
In some circumstances, “borderline” PH might indicate early
pulmonary vascular disease, especially when PAWP is low
and transpulmonary gradient and PVR are elevated.
However, the term “borderline PH” would not be useful in
patients with left heart disease and elevated PAWP levels.
The natural history of patients with PAPm values between
21 and 24 mm Hg has not been widely studied. One
exception are patients with the scleroderma spectrum of
disease, in whom the presence of “borderline” pressures
is associated with a high risk of future development ofmanifest PAH (9). The thera-
peutic consequences of such
ﬁndings, however, are unknown.
RECOMMENDATIONS.
 The general deﬁnition of
PH should remain un-
changed. PH is deﬁned by
PAPm 25 mm Hg at rest
measured by right heart
catheterization (RHC).
 There are still insufﬁcient
data to introduce the term
“borderline PH” for patients
with PAPm levels between
21 and 24 mm Hg, espe-
cially because the prognostic
and therapeutic implica-
tions remain unknown.
 Patients with PAPm values
between 21 and 24 mm Hg
should be carefully fol-
lowed, in particular when
they are at risk for devel-
oping PAH (e.g., patients
with CTD, family mem-




hypertension [HPAH]).Should exercise-induced PH be reintroduced as part of
the PH deﬁnition? Before the 4thWSPH, PHwas deﬁned
by resting PAPm >25 mm Hg or PAPm with exercise
>30mmHg. Potential weaknesses of that deﬁnition included
the fact that the level, type, and posture of exercise had not
been speciﬁed. Furthermore, the normal exercise PAP varies
with age. In a systematic review of the available literature (5),
there were no signiﬁcant differences in PAP at rest according
to age groups; however, during exercise, PAPm was signiﬁ-
cantly higher in older patients (>50 years of age). Based on
these data, a task force at the 4thWSPH concluded that it was
impossible to deﬁne a cutoff value for exercise-induced PH
and recommended eliminating this criterion (1).
Since 2008, several studies have shed more light on
exercise-induced PH (10,11), but there is still uncertainty
about the most suitable exercise protocol and cutoff levels. In
addition, prognostic value and therapeutic consequences of
exercise-induced PH in the setting of normal resting
hemodynamics have not been elucidated.
RECOMMENDATIONS ON EXERCISE-INDUCED PH.
 Because of the lack of a suitable deﬁnition, an exercise
criterion for PH should not be reintroduced at the
present time.
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exercise-induced elevations in PAPm and PVR have
prognostic and therapeutic implications.
Should PVR be included in the deﬁnition of PH/PAH?
HARMONIZATION OF PVR UNITS.Although PA is always given as mm Hg, various units
are used for PVR, most frequently dyn∙s∙cm5 and
Wood units (mm Hg/l∙min). Consistency would be
useful, and the working group suggested using Wood
units (WU), which can be directly derived from PAP
and cardiac output (CO) measurements without
multiplication with the factor 80. The use of SI units is
not endorsed because they are not commonly being
used for hemodynamics in clinical practice.According to a recent analysis (12), normal PVR at rest is
to some extent age dependent, but PVR >2 WU can be
considered elevated in all age populations. In the current
U.S. guidelines, PVR >3 WU is used as part of the
hemodynamic deﬁnition of PAH (3).
The working group members unanimously agreed that the
general deﬁnition of PH should be kept as simple and as
broad as possible. Some PH populations (for instance,
patients with elevated PAWP levels or patients with high
pulmonary blood ﬂow) may have elevated PAP but normal
PVR. Thus, PVR should not be part of the general deﬁni-
tion of PH.
However, the working group members proposed to
include PVR in the hemodynamic deﬁnition of PAH for the
following reasons: 1) including PVR underscores the need
to base the deﬁnition of PH on invasive measurements
(i.e., RHC); 2) including PVR makes PAWP (or left
ventricular end-diastolic pressure [LVEDP]) measurements
mandatory; 3) including PVR requires measurements of
CO, which would be a substantial advantage because it is
current practice in many nonexpert centers to perform
RHCs without measuring CO; 4) including PVR will
exclude high ﬂow conditions with normal PVR and without
pulmonary vasculopathy from the PAH deﬁnition; and
5) including PVR will lower the likelihood of patients with
left heart disease of being labeled as having PAH.
RECOMMENDATIONS ON PVR.
 To avoid the use of various units, PVR should be given
in WU.
 PVR should not become part of the general PH
deﬁnition.
 PVR should be included in the hemodynamic char-
acterization of patients with PAH as follows: patients
with PAH are characterized by pre-capillary PH (i.e.,
PAPm 25 mm Hg, PAWP 15 mm Hg, and
elevated PVR [>3 WU]).
 Although the upper level of normal PVR is approxi-
mately 2 WU, the PVR cutoff value for PAH should
be kept at 3 WU because patients with lower PVR
levels are unlikely to have PAH (this is consistent withsetting the cutoff for PAPm at 25 mm Hg, despite the
upper limit of normal being 20 mm Hg).
Is PAWP of 15 mm Hg appropriate to distinguish be-
tween pre-capillary and post-capillary PH and how should
PAWP be measured? PAWP/PAOP/PCWPdHARMONIZTION
OF TERMINOLOGY.The term pulmonary capillary wedge pressure
(PCWP) is widely used in the medical literature. For
measurement of this pressure, balloon occlusion occurs
in the pulmonary arteries, and the obtained value is not
equal to the pulmonary capillary pressure in non-
occluded areas. Thus, the term PCWP is misleading.
Better terms are pulmonary artery occlusion pressure
(PAOP) and PAWP. The working group prefers the
latter term because the short versions “wedge” and
“wedge pressure” are well established in daily clinical
practice, even in non–English-speaking countries.Current guidelines recommend using a PAWP (or
LVEDP) 15 mm Hg to deﬁne pre-capillary PH. Higher
PAWP values are commonly viewed as indicators of left
heart disease. However, patients with the diagnosis of heart
failure with preserved ejection fraction (HFpEF) can have
a resting PAWP <15 mm Hg and patients with features
otherwise indicating the presence of PAH may present with
higher PAWP values (13). In addition, PAWP measure-
ments vary between centers, and standardization is necessary
to ensure comparisons of patient populations.
STANDARDIZATION OF PAWP MEASUREMENTS. PAWP mea-
surements may be largely affected by swings in the intra-
thoracic pressure, especially in patients with lung disease.
This effect is least pronounced at the end of a normal
expiration, which is the point at which PAWP should be
determined. Many available devices do not provide end-
expiratory but digitized mean PAWP and therefore tend
to underestimate the PAWP. For standardization of PAWP
measurements, values should be determined at the end of
normal expiration (breath holding is not required). Ideally,
high-ﬁdelity tracings on paper should be used, rather than
small moving tracings on a cardiac monitor.
Normal PAWP values have been explored since the
advent of cardiac catheterization and have been found to
range from 5 to 12 mm Hg in healthy volunteers. However,
these data were generated in younger patients, and it remains
unclear whether there is a physiological increase in PAWP
with aging. In a comprehensive analysis of the medical
literature, Kovacs et al. (12) found that PAWP at rest was
independent of age, with values of 9  2 mm Hg found in
patients ranging from <24 to 70 years. Of note, the data
of the oldest patient population were derived from 17
patients only. Prasad et al. (14) performed a small but
meticulous study comparing hemodynamics and LV func-
tion in elderly patients with and without HFpEF, demon-
strating that the normal PAWP slightly increased with age,
although usually not beyond 15 mm Hg. Most importantly,
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HFpEF. On the basis of these and other data, it has been
suggested to lower the PAWP cutoff for pre-capillary PH to
12 mm Hg. Reasons to reduce the PAWP threshold to
12 mm Hg include the notion that PAWP of 15 mm Hg is
associated with a higher chance of misclassifying patients
with HFpEF as PAH and that the use of 15 mm Hg has
probably contributed to the labeling of patients with HFpEF
as PAH with consequences for medical therapy as well as
inclusions in clinical trials.
On the other hand, PAWP 15 mm Hg has a high
sensitivity to identify patients with pre-capillary PH, and
this cutoff value has been used for decades and has been
widely memorized among physicians. Almost all PAH trials
have included patients with PAWP 15 mm Hg, which
means that the safety and efﬁcacy of PAH drugs have been
evaluated in this patient population. Lowering the PAWP
threshold to 12 mm Hg decreases the likelihood of falsely
labeling patients with PH due to HFpEF as PAH but at the
same time increases the rate at which the presence of PAH is
mistakenly excluded.
There is no single PAWP value that allows for correct
classiﬁcation of all patients. PAWP is not a constant number
but a biological variable that is affected by various factors,
including ﬂuid balance, intrathoracic pressure, and others. In
many patients with left heart disease, it will be possible to at
least temporarily lower PAWP below 15 mm Hg with
meticulous afterload reduction and diuretic medication (15).
A comprehensive assessment of the patient’s medical history
and risk factors together with echocardiographic assessment
will provide a more reliable diagnosis than a single PAWP
(or LVEDP) measurement. The presence of clinical risk
factors (systemic hypertension, older age, obesity, diabetes
mellitus, obstructive sleep apnea, coronary artery disease),
atrial ﬁbrillation, and echocardiographic ﬁndings such as left
atrial enlargement or LV hypertrophy indicate a high like-
lihood of HFpEF (16).
A recent study showed that more than 50% of the patients
with PH and PAWP 15 mm Hg had LVEDP values
>15 mm Hg during simultaneous right and left heart
catheterization (17). These data raised a debate as to
whether the hemodynamic classiﬁcation as pre- or post-
capillary PH might be improved with routine LVEDP
measurements. The additional risks and costs associated
with routine left heart catheterizations are considerable but
might be offset by a more accurate diagnosis and the
avoidance of the expensive and potentially harmful use of
PAH medications in patients with HFpEF. The working
group felt that the current evidence does not support rec-
ommending left heart catheterization in all patients with
PAH, especially when neither the patient’s history nor
clinical and echocardiographic ﬁndings suggest the presence
of LV dysfunction. However, the threshold to perform
left heart catheterization should be low in patients with
echocardiographic signs of systolic and/or diastolic LV
dysfunction as well as in patients with risk factors forcoronary heart disease or HFpEF. In addition, the ﬁnding of
an elevated PAWP in a patient when this is unexpected
(normal left atrial size, absence of echocardiographic markers
of elevated LV ﬁlling pressures, absence of risk factors for
HFpEF) should prompt the performing physician to
measure LVEDP to avoid misclassiﬁcation.
RECOMMENDATIONS FOR PAWP AT REST.
 The working group does not recommend lowering the
threshold to 12 mm Hg in clinical practice.
 The cutoff for pre-capillary PH should remain at
15 mm Hg because this value has been used in
almost all clinical trials generating evidence for the
safety and efﬁcacy of PAH-targeted therapies in
patients fulﬁlling these criteria.
 Invasive hemodynamics need to be placed in clinical
and echocardiographic context with regard to proba-
bility of existence of left heart disease.
 The current evidence does not support recommending
left heart catheterization in all patients with PAH.
Should ﬂuid or exercise challenge be used to distinguish
patients with PAH from patients with PH due to LV
dysfunction? SHOULD FLUID CHALLENGE BE USED TO
UNMASK LV DIASTOLIC DYSFUNCTION? The effect of volume
challenge on left-sided end-diastolic pressure has been
a subject of interest for some time. Studies in healthy indi-
viduals have shown that administration of 1 liter of saline over
6 to 8 min raised the PAWP by a maximum of 3 mm Hg
but not to >11 mm Hg (18). In contrast, in a population at
high risk for diastolic dysfunction, administration of 500 ml
of saline over 5 min was able to reveal patients in whom the
PAWP increased to >15 mm Hg (19).
Thus, ﬂuid challenge may identify patients with HFpEF
but normal PAWP at baseline and may help reduce the
number of inappropriate diagnoses of PAH in patients
with LV diastolic dysfunction. A ﬂuid bolus of 500 ml
administered over a period of 5 to 10 min appears to be
safe and seems to discriminate patients with PAH from
those with LV diastolic dysfunction (20). Larger volumes,
in contrast, may cause the PAWP to rise even in healthy
volunteers (21). The diagnostic performance (sensitivity,
speciﬁcity, and positive and negative predictive values) of
ﬂuid challenge has not yet been sufﬁciently evaluated, and
the same is true for the safety of ﬂuid challenge in patients
with severe PH as well as in patients with HFpEF. In
addition, ﬂuid challenge adds another layer of complexity
to RHC.
RECOMMENDATION ON FLUID CHALLENGE FOR UNMASKING
HFPEF.
 Fluid challenge may be useful in identifying patients
with occult HFpEF, but this technique requires
meticulous evaluation and standardization before its use
in clinical practice can be recommended.
 Current evidence suggests that administration of 500
ml of ﬂuid over 5 to 10 min is safe and may help to
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LV diastolic dysfunction. The results of this test,
however, must be interpreted with caution and should
not be used alone to discard a diagnosis of PAH.
SHOULD HEMODYNAMICS BE ASSESSED AT EXERCISE TO
UNMASK LV DIASTOLIC DYSFUNCTION? Exercise, with wide
swings in airway and pleural pressures, poses particular
technical challenges in recording and interpreting cardiac
pressures, and few studies have systematically analyzed the
PAWP changes during exercise. In a study of healthy non-
athletes, the mean wedge pressure rose by up to 5 mm Hg
with exercise but did not exceed 15 mm Hg (22). In well-
trained athletes, recumbent exercise signiﬁcantly increased
the PAWP, reaching 20 to 25 mm Hg in several individuals
(23). In a more recent study on exercise-induced PH, Tolle
et al. (11) found PAWP values >15 mm Hg in approxi-
mately half of the healthy control group as well as in patients
with exercise-induced or resting PH.
Borlaug et al. (24) studied the effects of exercise on
hemodynamics in patients with exertional dyspnea and
presumed HFpEF but normal resting PAWP levels. At rest,
patients with HFpEF had slightly higher PAWP (11  2 vs.
9  3 mm Hg in controls without cardiac disease). During
exercise, end-expiration PAWP rose to 32  6 mm Hg in
patients with HFpEF compared with 13  5 mm Hg in
controls (24). In addition, a recent study suggested that
exercise hemodynamics may be useful in distinguishing
between PAH and PH associated with LV diastolic
dysfunction in patients with the scleroderma (SSc) spectrum
of disease (25).
Thus, exercise hemodynamics may identify patients with
HFpEF with normal PAWP at rest. However, it is
cumbersome and time consuming to exercise patients with
a catheter in place, reading of the PAWP during exercise is
difﬁcult, and there has been no standardization on the level
of exercise, type of exercise, position at exercise, and normal
values for various ages.
RECOMMENDATION ON EXERCISE CHALLENGE TO UNMASK
HFPEF.
 It is likely that exercise hemodynamics will be useful in
uncovering HFpEF. However, further evaluation,
standardization, and comparison with volume chal-
lenge are necessary before their use in clinical practice
can be endorsed.Additional Recommendations for RHC
Although current guidelines and textbooks recommend
RHC for the diagnostic evaluation of patients with PH,
speciﬁc recommendations on how to perform this procedure
are rare. The following points should be noted.
 RHC in patients with PH can be technically demanding
and has been associated with serious, sometimes fatal,complications (26). Thus, this invasive diagnostic
procedure should be performed in expert centers.
 Every RHC should include a comprehensive hemo-
dynamic assessment, including measurements of
pressures in the right atrium, right ventricle, and PA;
in the “wedge” position; and CO and mixed-venous
oxygen saturation.
 The zero level of the pressure transducer varies among
centers and should be standardized for future research
because the level of the transducer has an important
impact on the hemodynamic results, especially on right
atrium pressure and PAWP (27). The working group
recommends zeroing the pressure transducer at the
midthoracic line in a supine patient halfway between
the anterior sternum and the bed surface. This repre-
sents the level of the left atrium.
 The balloon should be inﬂated in the right atrium
from where the catheter should be advanced until it
reaches the PAWP position. Repeated deﬂations and
inﬂations of the catheter should be avoided because
this has been associated with ruptures of PAs (26).
The PAWP should be recorded as the mean of 3
measurements at end-expiration.
 The gold standard for CO measurement is the direct
Fick method, which requires direct measurement of
the oxygen uptake, a technique that is not widely
available. Therefore, it has become common practice in
many centers to use the indirect Fick method, which
uses estimated values for oxygen uptake derived from
tables. This approach is acceptable but lacks reliability.
Therefore, the preferred method of measuring CO is
thermodilution, which has been shown to provide
reliable measurements even in patients with very low
CO and/or severe tricuspid regurgitation (28).
 Oximetry (i.e., stepwise assessment of oxygen satura-
tion) should be performed in every patient with a PA
oxygen saturation >75% and whenever a cardiac left-
to-right shunt is suspected.
 Pulmonary vasoreactivity testing for identiﬁcation of
calcium channel blocker “responders” is recommended
only for patients with IPAH. In all other forms of
PAH or PH, pulmonary vasoreactivity testing is not
recommended unless it is completed for scientiﬁc
purposes because “responders” are exceedingly rare
among these patients and the results can be misleading
(29). Inhaled nitric oxide at 10 to 20 parts per million is
the gold standard for pulmonary vasoreactivity testing
(30); intravenous epoprostenol (2 to 12 ng/kg/min),
intravenous adenosine (50 to 350 mg/min), and inhaled
iloprost (5 mg) can be used as alternatives (31,32). The
use of oxygen, calcium channel blockers, phosphodi-
esterase 5 inhibitors, or other vasodilators for acute
pulmonary vasoreactivity testing is discouraged.
 Pulmonary angiography can be part of the RHC but
should be performed after all hemodynamic assess-
ments have been completed.
Figure 1 Diagnostic Approach to Pulmonary Hypertension
BGA ¼ blood gas analysis; CHD ¼ congenital heart disease; CTD ¼ connective tissue disease; CTEPH ¼ chronic thromboembolic pulmonary hypertension; DLCO ¼ diffusion
capacity of the lung for carbon monoxide; ECG ¼ electrocardiogram; HR-CT ¼ high-resolution computed tomography; PA ¼ pulmonary angiography; PAH ¼ pulmonary arterial
hypertension; PAPm ¼ mean pulmonary artery pressure; PAWP ¼ pulmonary arterial wedge pressure; PCH ¼ pulmonary capillary hemangiomatosis; PEA ¼ pulmonary endar-
terectomy; PFT ¼ pulmonary function testing; PH ¼ pulmonary hypertension; PVOD ¼ pulmonary veno-occlusive disease; PVR ¼ pulmonary vascular resistance; RHC ¼ right
heart catheter; RV ¼ right ventricle; V/Q ¼ ventilation/perfusion; x-ray ¼ chest radiograph.
JACC Vol. 62, No. 25, Suppl D, 2013 Hoeper et al.
December 24, 2013:D42–50 Definition and Diagnosis of PH
D47Diagnostic Approach in Patients With
Clinical Suspicion of PH/PAH
The most fundamental principles in the diagnostic workup
of patients with clinical suspicion of PH/PAH remain
unchanged. PH/PAH should be suspected in any patient
with otherwise unexplained dyspnea on exertion, syncope,and/or signs of right ventricular dysfunction. Transthoracic
echocardiography continues to be the most important
noninvasive screening tool to assess the possibility of PH,
but RHC remains mandatory to establish the diagnosis. A
diagnosis of PAH requires the exclusion of other causes of
PH, and the working group proposes a slightly modiﬁed
version of the diagnostic algorithm proposed in the 2009
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version has been simpliﬁed and, in some aspects, is more
speciﬁc. The pathway leading from ventilation/perfusion
scintigraphy to pulmonary veno-occlusive disease has been
deleted (33), and diffusing capacity of the lung for carbon
monoxide (DLCO) measurements have been added to the
initial assessment because spirometry alone does not always
reveal parenchymal lung disease, for instance, in patients
with combined pulmonary ﬁbrosis and emphysema (34–36).
A comprehensive workup for PH requires expertise and
should be performed at expert centers (2).Early Identiﬁcation of Patients With PAH
Sporadic cases (IPAH). Despite increasing awareness,
there is often considerable delay between onset of symptoms
and diagnosis of IPAH. In the recent REVEAL (Registry to
Evaluate Early and Long-Term PAH Disease Manage-
ment) registry, 21% of patients had symptoms for >2 years
before diagnosis (37,38). The vast majority of patients
diagnosed with IPAH are in World Health Organization
functional classes III and IV (37,39–41), which have been
shown to predict poorer survival (42,43). The nature of
patients formally diagnosed with IPAH has also changed
over recent years, at least in the Western world, with
a signiﬁcant increase in age and number of comorbidities
(41,44,45). Identifying patients with IPAH earlier in the
disease process is likely to be beneﬁcial, allowing targeted
therapies to be started before the development of signiﬁcant
right heart failure (46). Screening is possible in well-deﬁned
patient groups at high risk of developing PAH, but this
approach is not feasible in the wider population. Identifying
patients with IPAH earlier relies on health care professionals
having awareness of the condition.
Hereditary cases (HPAH). Approximately 20% of patients
with sporadic IPAH and 70% of patients with HPAH have
a mutation in bone morphogenetic protein receptor 2
(BMPR2), and additional genes associated with HPAH have
recently been identiﬁed (47,48), which raises the possibility of
family screening (49). However, because of reduced pene-
trance, the lifetime risk of developing PAH is approximately
20% in BMPR2 mutation carriers (50). The beneﬁts of
genetic testing are therefore not certain. A negative test in the
context of a known mutation in a family member is reassur-
ing, whereas a positive test can create signiﬁcant psycholog-
ical issues (51). Furthermore, the approach to monitoring
known mutation carriers for the development of PAH is not
clear. Interval echocardiography of mutation carriers has been
suggested (53), although in the absence of evidence for
beneﬁt of targeted therapies in truly asymptomatic patients, it
could be argued that echocardiography should be reserved
only for symptomatic carriers. Most importantly, expert
counseling should accompany any family screening program.
Detection of PAH and screening in high-risk populations.
Various other groups of patients may be considered at high
risk of developing PAH and, as such, may be candidates forearly detection. These include patients with CTD, congenital
heart disease, chronic liver disease, and HIV infection.
Except for patients with the SSc spectrum of disease, no new
evidence has been generated; therefore, previous recom-
mendations have not been modiﬁed.
Screening for PAH in patients with the SSc spectrum of
disease. Current guidelines recommend regular screening
by echocardiography in patients with SSc spectrum of
diseases (deﬁned as patients with systemic sclerosis, mixed
connective tissue disease, or other CTDs with prominent
scleroderma features such as sclerodactyly, nail fold capillary
abnormalities, SSc-speciﬁc autoantibodies) (2,4). No such
guidelines exist for other CTDs.
The DETECT (Evidence-based detection of pulmonary
arterial hypertension in systemic sclerosis) study recently
evaluated a 2-step approach in patients with SSc spectrum
disorders with DLCO60% and disease duration of>3 years
(52). The ﬁrst step used a simple screening test, such as the
presence of telangiectasia, anticentromere antibodies, right-
axis deviation on electrocardiogram, and low DLCO and
serum biomarkers (urate and N-terminal pro–B-type natri-
uretic peptide [NT-proBNP]), which gave a sensitivity of
97% (i.e., a low likelihood of falsely excluding PAH). Step 2
was echocardiography (tricuspid regurgitation jet and right
atrium area) in patients at risk, followed by RHC. With this
algorithm, the number of missed PAH cases was 4%,
compared with 29% with the echocardiography-based
approach recommended in the current European Respiratory
Society/European Society of Cardiology guidelines, suggest-
ing that using a broader panel of diagnostic tools provides
more reliable information than echocardiography alone.
The DETECT algorithm is not yet validated in patients
with DLCO >60%. Other choices include a combination of
echocardiogram, NT-proBNP, and pulmonary function
testing (PFT) parameters, which is summarized in the
recently published recommendations on screening and early
detection of CTD-associated PAH (53,54).
Recommendations on screening of high-risk populations
for PAH.
 Annual screening for PAH is recommended in
(cardiopulmonary) asymptomatic patients with the SSc
spectrum of diseases, although there is a lack of
evidence-based data.
 Screening of patients with the SSc spectrum of diseases
without clinical signs and symptoms of PH should
include a 2-step approach using clinical assessment for
the presence of telangiectasia, anticentromere anti-
bodies, PFT and DLCO measurements, electrocar-
diogram, and biomarkers (NT-proBNP and uric acid)
in the initial stage, followed by echocardiography and
consideration of RHC in patients with abnormal ﬁnd-
ings, although there is a lack of data withDLCO>60%.
 The above mentioned screening programs for patients
with SSc should be part of a scientiﬁc protocol, or
a registry, whenever possible.
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and symptoms of PH should be evaluated by RHC.Summary and Conclusions
The diagnostic approach to PH proposed at the 4th WSPH
has proved useful and largely successful. The general hemo-
dynamic deﬁnition of PH (PAPm25mmHg at rest) should
not be changed. Patients with PAPm values between 21 and
24 mm Hg should be carefully followed, but the term
“borderline PH” should be avoided because these patients
do not have PH. PVR >3 WU has been added as a hemo-
dynamic criterion for PAH, in an attempt to provide a clearer
distinction from other forms of PH. RHC remains an
essential tool for the diagnostic workup of patients with PH,
and the working group has made several proposals for further
standardization of this procedure. Reintroducing exercise
criteria for patients with normal hemodynamics at rest but
elevated PA pressures during exercise is not recommended
because it is currently impossible to deﬁne appropriate cutoff
levels and there have been few studies assessing what is path-
ological in terms of affecting exercise capacity and survival.
Data from all over the world indicate that the majority of
patients are still diagnosed in a late stage of the disease, and
this is not expected to change in the near future. The most
signiﬁcant progress has been made in patients with SSc, for
whom the DETECT study has provided important data on
screening for PAH (52).
The increased awareness has led to a changing pattern of
patients referred for evaluation of PH/PAH. The patients
tend to be older and have more comorbidities (41,44,45).
Arguably, the majority of these patients have LV diastolic
dysfunction as the leading cause of PH, but our current
diagnostic tools are often insufﬁcient to provide a clear
distinction between PAH and PH due to left heart disease.
At the next world meeting in 2018, we hope to have data
from well-conducted trials to tell us whether and how ﬂuid
challenge, exercise hemodynamics, or other novel tools will
help us to paint a clearer picture.
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